27 January 2023 - The Inflation Reduction Act mandated the creation of a Drug Price Negotiation Program focused on developing a process for Medicare to engage manufacturers in efforts to reduce the prices of certain products paid for under Medicare Part B and Part D. 

While there are several limitations to which drugs may be selected and what criteria CMS can use within the new Drug Price Negotiation Program interpretation and implementation of this legislation creates new opportunities for engaging patients and caregivers in a meaningful way.

Read Health Affairs article